AdventHealth launches 1st-of-kind cancer vaccine trial

Orlando-based AdventHealth Cancer Institute has initiated a pioneering Phase II bladder cancer vaccine trial utilizing patient-specific mRNA vaccines.

Trial participants will receive pembrolizumab alongside a personalized immunotherapy injection tailored to the unique proteins in each patient's tumors. The treatment regimen includes infusions every six weeks for one year, followed by a vaccine injection every three weeks for a total of nine doses.

"This vaccine represents the pinnacle of precision medicine," stated Guru Sonpavde, MD, medical director of genitourinary oncology at AdventHealth Cancer Institute and a member of the trial’s global steering committee. He emphasized the potential of this approach to significantly improve patient outcomes by targeting the specific characteristics of each individual's cancer.